Skip to main content
Erschienen in: International Urology and Nephrology 1/2007

01.03.2007 | Original Paper

Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis

verfasst von: Tapani Salonen, Tuomo Reina, Heikki Oksa, Pekka Rissanen, Amos Pasternack

Erschienen in: International Urology and Nephrology | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Dialysis treatment requires considerable resources and it is important to improve the efficiency of care.

Methods

Files of all adult end-stage renal disease (ESRD) patients who entered dialysis therapy between 1991 and 1996, were studied and all use of health care resources was recorded. A total of 138 patients started with in-center hemodialysis (HD) and 76 patients with continuous ambulatory peritoneal dialysis (CAPD). Four alternative perspectives were applied to assess effectiveness. An additional analysis of 68 matched CAPD-HD pairs with similar characteristics was completed.

Results

Cost-effectiveness ratios (CER; cost per life-year gained) were different in alternative observation strategies. If modality changes and cadaveric transplantations were ignored, annual first three years’ CERs varied between $41220–61465 on CAPD and $44540–85688 on HD. If CAPD-failure was considered as death, CERs were $34466–81197 on CAPD. When follow-up censored at transplantation but dialysis modality changes were ignored, CERs were $59409–95858 on CAPD and $70042–85546 on HD. If observation censored at any change of primarily selected modality, figures were $57731–66710 on CAPD and $74671–91942 on HD. There was a trend of lower costs and better survival on CAPD, the only exception was the strategy in which technical failure of modality was considered as death. Figures of the matched CAPD-HD pairs were very close to the figures of the entire study population.

Conclusions

Compared to HD, CERs were slightly lower on CAPD.
Literatur
1.
Zurück zum Zitat Goeree R, Manalich J, Grootendorst P, Beecroft M, Churchill D (1995) Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 18:455–464PubMed Goeree R, Manalich J, Grootendorst P, Beecroft M, Churchill D (1995) Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 18:455–464PubMed
2.
Zurück zum Zitat Manns B, Taub K, Donaldson C (2000) Economic evaluation and end-stage renal disease: from basics to bedside. Am J Kidney Dis 36:12–28PubMed Manns B, Taub K, Donaldson C (2000) Economic evaluation and end-stage renal disease: from basics to bedside. Am J Kidney Dis 36:12–28PubMed
4.
Zurück zum Zitat Garella S (1997) The costs of dialysis in the USA. Nephrol Dial Transplant 12:S10–S21 Garella S (1997) The costs of dialysis in the USA. Nephrol Dial Transplant 12:S10–S21
5.
Zurück zum Zitat Mallick N (1997) The costs of renal services in Britain. Nephrol Dial Transplant 12:S25–S28CrossRef Mallick N (1997) The costs of renal services in Britain. Nephrol Dial Transplant 12:S25–S28CrossRef
6.
Zurück zum Zitat Chugh K, Jha V (1995) Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int 48:S7–S13 Chugh K, Jha V (1995) Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int 48:S7–S13
7.
Zurück zum Zitat Laupacis A, Keown P, Pus N et al (1996) A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50:235–242PubMed Laupacis A, Keown P, Pus N et al (1996) A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50:235–242PubMed
8.
Zurück zum Zitat Karlberg I, Nyberg G. (1995) Cost-effectiveness studies of renal transplantation. Int J Technol Assess Health Care 11:611–622PubMedCrossRef Karlberg I, Nyberg G. (1995) Cost-effectiveness studies of renal transplantation. Int J Technol Assess Health Care 11:611–622PubMedCrossRef
9.
Zurück zum Zitat de Wit G, Ramsteijn P, de Charro F (1998) Economic evaluation of end stage renal disease treatment. Health Policy 44:215–232PubMedCrossRef de Wit G, Ramsteijn P, de Charro F (1998) Economic evaluation of end stage renal disease treatment. Health Policy 44:215–232PubMedCrossRef
10.
Zurück zum Zitat Lee H, Manns B, Taub K et al (2002) Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 40:611–622PubMedCrossRef Lee H, Manns B, Taub K et al (2002) Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 40:611–622PubMedCrossRef
11.
Zurück zum Zitat Sennfalt K, Magnusson M, Carlsson P (2002) Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis. Perit Dial Int 22:39–47PubMed Sennfalt K, Magnusson M, Carlsson P (2002) Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis. Perit Dial Int 22:39–47PubMed
12.
Zurück zum Zitat Mendelssohn D, Mullaney S, Jung B, Blake P, Mehta R (2001) What do American nephrologists think about dialysis modality selection? Am J Kidney Dis 37:22–29PubMed Mendelssohn D, Mullaney S, Jung B, Blake P, Mehta R (2001) What do American nephrologists think about dialysis modality selection? Am J Kidney Dis 37:22–29PubMed
13.
Zurück zum Zitat Nissensson AR, Prichard S, Cheng IKP et al (1993) Non-medical factors that impact on ESRD modality selection. Kidney Int 43:S120–S127 Nissensson AR, Prichard S, Cheng IKP et al (1993) Non-medical factors that impact on ESRD modality selection. Kidney Int 43:S120–S127
14.
Zurück zum Zitat Coyte P, Young L, Tipper B et al (1996) An economic evaluation of hospital-based hemodialysis and home-based peritoneal dialysis for pediatric patients. Am J Kidney Dis 27:557–565PubMed Coyte P, Young L, Tipper B et al (1996) An economic evaluation of hospital-based hemodialysis and home-based peritoneal dialysis for pediatric patients. Am J Kidney Dis 27:557–565PubMed
15.
Zurück zum Zitat Dor A, Held P, Pauly M (1992) The Medicare cost of renal dialysis: evidence from a statistical cost function. Med Care 30:879–891PubMedCrossRef Dor A, Held P, Pauly M (1992) The Medicare cost of renal dialysis: evidence from a statistical cost function. Med Care 30:879–891PubMedCrossRef
16.
Zurück zum Zitat Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A (2003) Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis 42:1228–1238PubMedCrossRef Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A (2003) Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis 42:1228–1238PubMedCrossRef
17.
Zurück zum Zitat Jaar B, Coresh J, Plantinga L et al (2005) Comparing the Risk for Death with Peritoneal Dialysis and Hemodialysis in a National Cohort of Patients with Chronic Kidney Disease. Ann Intern Med 143:174–183PubMed Jaar B, Coresh J, Plantinga L et al (2005) Comparing the Risk for Death with Peritoneal Dialysis and Hemodialysis in a National Cohort of Patients with Chronic Kidney Disease. Ann Intern Med 143:174–183PubMed
Metadaten
Titel
Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis
verfasst von
Tapani Salonen
Tuomo Reina
Heikki Oksa
Pekka Rissanen
Amos Pasternack
Publikationsdatum
01.03.2007
Verlag
Kluwer Academic Publishers
Erschienen in
International Urology and Nephrology / Ausgabe 1/2007
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-006-9141-2

Weitere Artikel der Ausgabe 1/2007

International Urology and Nephrology 1/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.